Vancomycin

In the clinical response to the problem of Gram-positive bacterial resistance, glycopeptide antibiotics have always been the core treatment option. As a classic representative of this category, vancomycin exerts its bactericidal effect by inhibiting the biosynthesis of peptidoglycan in the bacterial cell wall, and has high activity against methicillin-resistant *Staphylococcus aureus* (MRSA), penicillin-resistant *Streptococcus pneumoniae* and other multi-drug resistant Gram-positive bacteria. It is mainly used clinically for sepsis, infective endocarditis, osteomyelitis, pneumonia and skin and soft tissue infections caused by drug-resistant bacteria, and is one of the first-choice drugs for immunocompromised patients with drug-resistant Gram-positive bacterial infections. It can also be used for infection prevention in the perioperative period of colon surgery and other operations, covering the infection treatment needs of all age groups including adults and children.

The global vancomycin market size has maintained a steady growth trend in recent years. In 2023, the total market size was approximately USD 1.28 billion, with a compound annual growth rate maintained at around 3.7%. The domestic market size exceeds RMB 2.7 billion, among which injections are the main application dosage form, accounting for more than 96% of the overall market share. In terms of the competitive landscape, the original research product still accounts for about 23% of the high-end medical market share, and domestic generic preparations have achieved large-scale supply. At present, nearly 30 domestic enterprises have obtained approval for the marketing of vancomycin preparations, and 6 enterprises have their active pharmaceutical ingredients registered through the CDE. The overall supply is sufficient, and the price has been adjusted through multiple rounds of centralized procurement, significantly improving the accessibility of medication for patients.

The original research enterprise of vancomycin is Eli Lilly and Company, and the original research trade name is Vancocin®. Its core compound patent has expired globally. The original research dosage form is mainly powder for injection, with mainstream specifications including 0.5g and 1.0g. It has been included in the *Catalogue of Reference Preparations of Chemical Drugs* in China, and is also a reference preparation recognized by the FDA. At present, there are 12 domestic registration numbers for vancomycin active pharmaceutical ingredients, 8 of which are in status A and can be used in association with preparation declaration. Both domestic and original research preparations have been approved for marketing in China for many years. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of vancomycin impurity reference standards, supporting the full-process needs such as consistency evaluation, quality research and release testing. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can efficiently match the quality control needs of the R&D and production ends.